Eosinophilic Esophagitis Endotype Stratification via Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for eosinophilic esophagitis (EoE) lack specificity, as they are not tailored to individual disease endotypes, leading to inadequate treatment responses due to patient heterogeneity.
Innovation Solution
Identification of three distinct EoE endotypes (mild, intermediate, and severe) based on gene expression analysis, allowing for personalized treatment approaches using proton pump inhibitors, anti-cytokine therapies, anti-ALOX15 therapies, and glucocorticoids tailored to each endotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard therapies (food elimination, topical glucocorticoids) are used for all EoE patients, then treatment coverage is broad, but treatment efficacy is insufficient due to patient heterogeneity and lack of tailoring to specific disease endotypes
Solution Approach 1:
The patent segments EoE patients into three distinct disease endotypes (EoEe1, EoEe2, EoEe3) based on gene expression profiles. Each endotype is characterized by specific gene signatures and responds differently to treatments. This segmentation enables tailored therapeutic strategies for each subgroup, improving overall treatment efficacy by matching therapies to specific disease mechanisms rather than applying uniform treatment to heterogeneous patient populations.
Solution Approach 2:
The patent uses gene expression parameter changes to differentiate disease endotypes. By measuring expression levels of specific genes (e.g., ALOX15, TSLP, ACTG2, PNLIPRP3) and comparing them against established thresholds, the system identifies which endotype a patient belongs to. This parameter-based classification enables precise treatment selection, such as recommending ALOX15 inhibitors for EoEe1, anti-cytokine therapies for EoEe2, and combination therapies for EoEe3.
2Adaptability or versatility
If gene expression analysis is performed to identify EoE endotypes, then personalized treatment can be achieved, but diagnostic complexity and cost increase
Solution Approach 1:
The diagnostic approach is segmented into three distinct endotype categories, each with defined gene expression thresholds. Rather than analyzing all genes simultaneously, the system focuses on specific gene panels (ALOX15, TSLP, ACTG2, PNLIPRP3) with established cutoff values. This segmented approach simplifies the diagnostic process while maintaining the ability to provide personalized treatment recommendations.
Solution Approach 2:
The patent establishes specific parameter thresholds for gene expression levels that define each endotype. For example, ALOX15 expression below a certain threshold indicates EoEe1, while elevated TSLP suggests EoEe2. These parameter changes transform complex gene expression data into discrete, actionable diagnostic categories, making the diagnostic process more manageable and interpretable for clinical decision-making.
Data Source
AI summary
The present invention relates to methods for identifying an EoE endotype of a patient and treating the patient with one or more therapies targeted to the patient's disease endotype; and related methods for stratifying patients for clinical trials.